The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the Aace System of Intensive Diabetes Self-Management—2002 Update

Feld, Stanley

doi:10.4158/ep.8.s1.40

Cited by 134 publications

(9 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the American Diabetes Association (ADA), HbA1c level of <7% as a goal of optimal blood glucose control 4 and the American Association of Clinical Endocrinologist has further recommended HbA1c level of <6.5% is the target goal. 5 One of the major risk factors of CVD in type 2 diabetic mellitus is dyslipidaemia. The indicators of diabetic dyslipidaemia include elevated level of triglycerides and LDL-C and low HDL-C.…”

Section: Introductionmentioning

confidence: 99%

Hba1c and Lipid Profile Levels in the Known Type 2 Diabetic Group in the Rural Region of Vidarbha, Maharashtra, India

Sarkar¹,

Meshram²

2017

jebmh

View full text Add to dashboard Cite

BACKGROUNDDiabetes Mellitus (DM) is a group of metabolic diseases in which there is high blood sugar levels over a prolonged period of time, and if early interventions are not taken, then it can cause many life-threatening complications like heart disease, stroke, kidney failure, damage to eyes, etc. Our aim is to determine HbA1c and Lipid profile level in the known type 2 diabetic group in the rural region of Vidarbha, Maharashtra, India, to see that as our study is a rural-based study and there is less pollution and stress factor compared to the cities whether it effects out study result or not. MATERIALS AND METHODSFBS, HbA1c, TC, HDL, LDL, VLDL, TG levels were evaluated. Total sample size 60 in between 30-40 years including males and females divided into two groups. 30 patients study group with known history of type 2 DM who attended the Medicine OPD and 30 age, sex matched healthy controls. Statistical analysis was done by using SPSS 17.0 version. RESULTSResults of serum lipid profile showed that mean values for TC, TG, HDL, LDL and VLDL in study group were 227.76±30. 72, 152.23 ± 40.94, 40.5 ± 6.43, 153.30 ± 27.70 and 33.00 ± 9.94 mg/dL. FBS showed significant positive correlation with HbA1c (p<0.002). HDL has significant negative correlation with HbA1c (p<0.008). CONCLUSIONEarly detection in the abnormalities of serum lipid profile and HbA1c can minimise the risk for micro and macroangiopathies in the known type 2 diabetic patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Hba1c and Lipid Profile Levels in the Known Type 2 Diabetic Group in the Rural Region of Vidarbha, Maharashtra, India

Sarkar¹,

Meshram²

2017

jebmh

View full text Add to dashboard Cite

show abstract

“…It was determined that as a result of this delay, 30% of the patients had microvascular and 21.3% had macrovascular complications, and 9.2% had myocardial infarction history prior to insulin treatment (9). In terms of an A1C lowering effect, insulin treatment (1.5-2.5%) is considered to be more effective than OADs (0.5-2.0%) (12)(13)(14). As per the recommendations of the Turkish Society of Endocrinology and Metabolism 2017 Guideline for Diagnosis, Treatment and Monitoring of Diabetes Mellitus and its Complications (15), new treatment regimens (the most effective being insulin) should be introduced rapidly in cases where glycemic targets cannot be achieved or maintained with the use of OADs as the first or second line treatment.…”

Section: Importance Of Timely Insulinizationmentioning

confidence: 99%

“…The combination of basal insulin and OAD is recommended for the initiation of insulin therapy in T2D by many guidelines (12,14,15,(18)(19)(20)52 The expert panel recommends insulin therapy intensification in the following cases:…”

Section: Switching From Basal Insulin To Biasp 30mentioning

confidence: 99%

Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

Akalın¹,

Aydın²,

Balci³

et al. 2018

Turk J Endocrinol Metab

View full text Add to dashboard Cite

The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin insufficiency and/or insulin resistance, delay beta cell damage/depletion, and prevent other metabolic co-morbidities and complications. In the current treatment algorithms, lifestyle changes (medical nutrition therapy, physical exercise) and oral anti-diabetics are followed by insulin therapy, which is considered a replacement therapy for Type 2 diabetes. Pre-mixed insulin preparations, which are an option for patients with poor blood glucose level control under oral anti-diabetics treatment, have been developed to meet both basal and prandial insulin needs by simulating the physiological changes in insulin levels. The consensus on the necessity of individualizing insulin therapy requires physicians to have a detailed knowledge of the various uses of insulin. Therefore, this comprehensive consensus statement has been prepared by a panel of expert endocrinologists from different regions of Turkey to help physicians use biphasic insulin aspart 30 in suitable patients at the right time. In this statement, expert panel opinions on (a) Recommendations for the appropriate initiation, titration, and intensification of insulin treatment, and (b) The treatment algorithms in initiation, titration, and intensification of biphasic insulin aspart 30 treatment and special conditions specific to changing treatment regimen are presented.Keywords: Biphasic insulin aspart 30; insulin intensification; premixed insulin; insulin analog Tip 2 diyabet (T2D) tedavisinde amaç, insülinin yetersiz salgısı ve/veya insülin direnci sonucu oluşan hiperglisemiyi ortadan kaldırmak, beta hücre harabiyetini/tükenişini yavaşlatmak, eşlik eden diğer metabolik sorunları düzeltmek ve komplikasyonları önlemektir. Güncel tedavi algoritmalarında yaşam tarzı değişikliği (tıbbi beslenme tedavisi, egzersiz) ve oral antidiyabetikler ile tedavi seçeneklerini izleyen aşamada yer alan insülin, T2D için bir yerine koyma tedavisi olarak değerlendirilmektedir. Hazır karışım insülinler, oral antidiyabetikler ile kan glukoz düzeyleri kontrol altına alınamayan hastaların tedavisinde yer alması önerilen tedavi seçeneklerinden olup, hem bazal hem de prandiyal insülin ihtiyacını fizyolojiye yakın biçimde karşılamak amacıyla geliştirilmişlerdir. İnsülin tedavisinin kişiye özel olması gerektiği konusundaki konsensüs, hekimlerin değişik insülinlerin kullanımları ile ilgili daha ayrıntılı bilgiye sahip olmalarını gerektirmektedir. Bu nedenle, ülkemiz koşullarında bifazik insülin aspart 30'un doğru hastada, doğru zamanda ve doğru biçimde kullanılmasını kolaylaştırmak ve hekimlere yardımcı olmak için Türkiye'nin farklı bölgelerinde görev yapmakta olan deneyimli endokrinologlardan oluşan bir uzman paneli tarafından, bu kapsamlı uzlaşı metni hazırlanmıştır. Bu uzlaşı metninde, uzman paneli görüşleri; a) İnsülin tedavisine uygun başlangıç, titrasyon ve yoğunlaştırma algoritma önerileri ve b) Bifazik insülin aspart 30 tedavisine özgü başlangıç, titrasyon ve yoğunlaştırma tedavi algor...

show abstract

“…This later could progress to cirrhosis and also rarely to Hepatocellular Carcinoma (HCC). 1 Incidence of fatty liver disease in type 2 Diabetes Mellitus (T2DM) is significantly rising. Its incidence is increasing likely due to occurrence of obesity and insulin resistance and metabolic syndrome in Type 2 Diabetes Mellitus.…”

mentioning

confidence: 99%

Utility of Prostate Specific Antigen Values in Diagnosis and Management of Prostate Cancer

A.M.¹

2013

jemds

View full text Add to dashboard Cite

BACKGROUNDFatty liver disease or non-alcoholic steatosis affects a growing number of the adult diabetic population in developed countries. The main aim of this study was to understand the correlation of fatty liver disease in diabetics with its relation to dyslipidaemia, glycated haemoglobin (HbA1c) and increased BMI. MATERIALS AND METHODSThis is a retrospective cross-sectional study carried out in a tertiary hospital in Karad, Maharashtra, India, to evaluate the incidence of non-alcoholic steatosis (Fatty liver) in non-alcoholic Type 2 Diabetes Mellitus patients. Diagnosis of fatty liver was made on the basis of ultrasonography. This screening included a total of 100 randomly chosen diabetic patients. Of these 60 were male and 40 were female. RESULTSThe study subjects' BMI, lipid profile, HbA1c and USG was done to evaluate the co-relation between fatty liver, dyslipidaemia and increased BMI. There was a high incidence of dyslipidaemia, increased BMI and poor glycaemic control was noted in the subjects who had fatty liver. In this study, the females were known to have a higher incidence of fatty liver in comparison to males (56.5% females and 43.47% males). CONCLUSIONThis study concluded that there was a significant co-relation of fatty liver with diabetes mellitus type 2. There was also an increased incidence of fatty liver in diabetics with dyslipidaemia or poor glycaemic control or increased BMI. This screening process also suggests that the diabetic patients who were shown to have fatty liver had other co-morbidities, which could be a risk factor for progression of the disease.

show abstract

The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the Aace System of Intensive Diabetes Self-Management—2002 Update

Cited by 134 publications

References 65 publications

Hba1c and Lipid Profile Levels in the Known Type 2 Diabetic Group in the Rural Region of Vidarbha, Maharashtra, India

Hba1c and Lipid Profile Levels in the Known Type 2 Diabetic Group in the Rural Region of Vidarbha, Maharashtra, India

Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

Utility of Prostate Specific Antigen Values in Diagnosis and Management of Prostate Cancer

Contact Info

Product

Resources

About